Syngene Shares Hit 10% Lower Circuit as Q4 FY25 Net Profit Falls 3% YoY

Syngene International Ltd experienced a sharp decline on April 24, 2025, falling 9.73% to ₹677.10 at 9:17 AM on the BSE from the previous close of ₹750.05. The stock opened lower at ₹690.65 and touched an intraday low of ₹673.50, nearing its lower circuit limit of ₹675.05.

Q4 FY25 Result Snapshot

In the fourth quarter of FY25, Syngene International reported a 3% year on year decline in net profit, registering ₹183 crore versus ₹189 crore in the same period last year. Despite the dip in profitability, total income increased to ₹1,037 crore from ₹933 crore, reflecting a stable top-line growth.

For the full fiscal year, net profit stood at ₹496 crore, marginally down from ₹510 crore in FY24, while annual revenue reached ₹3,714 crore compared to ₹3,579 crore previously. This suggests a resilient financial performance amid broader economic and sectoral pressures.

Syngene’s board has proposed a final dividend of ₹1.25 per share for FY25, signaling continued confidence in the company’s financial stability and long-term outlook.

CEO Commentary- Resilience Amid Headwinds

Peter Bains, Syngene’s Managing Director and CEO, described the year’s performance as resilient, particularly in light of the downturn in US biotech funding that affected the first half.

He noted that the company returned to growth in the second half and anticipates early teens revenue growth in FY26, supported by a robust pipeline across discovery, development, and manufacturing services.

Inventory Balancing Weighs on Reported Numbers

Management pointed to inventory balancing in large molecule commercial manufacturing at the client level as a temporary drag on reported revenue. Adjusted for this, growth is expected to be stronger in the upcoming fiscal year.

About Syngene International

Syngene International Ltd is an innovation-driven contract research, development, and manufacturing organisation that provides integrated scientific services across the entire product lifecycle, from early discovery to commercial supply.

With a focus on customised, end-to-end solutions, Syngene collaborates closely with clients to offer R&D and manufacturing services that go beyond traditional outsourcing.

The company serves a wide range of industries, including pharmaceuticals, biotechnology, and life sciences, and is known for its cutting-edge capabilities in biologics, small molecules, and complex biologics manufacturing.

Read More: Tata Consumer Shares Fell Over 2%: Revenue Grew 17% in Q4FY25.

Conclusion

In conclusion, Syngene International Ltd’s performance in Q4 FY25 reflected a slight dip in profitability despite a solid rise in total income. The decline in net profit by 3% year-on-year, paired with the stable revenue growth, highlights the company’s ability to manage challenges in the market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.